- Healthgen Biotech Project HY-1003 Obtained the Orphan Drug Designation from U.S. FDA February 19, 2020, the project HY-1003, Recombinant human Alpha-1 Antitrypsin, a new bio-pharmaceutical independently developed by Wuhan Healthgen Biotechnology Corp.( hereinafter referred to as Healthgen Biotech) by its State-of-the-Art plant expression platform, had obtained th... Posted by Site editor|2020-03-25 LearnMore
- Application of plant-derived Recombinant Fibronectin in diagnose reagents Fibronectin (Fn), is mainly synthesized by liver and vascular endothelial cells, and widely found in animal plasma, body fluids and tissues. It's a large molecular glycoprotein with a molecular weight of 220-250 KD in monomer, 450 KD in dimer, and has various biological activ... Posted by Site editor|2020-02-21 LearnMore
- Healthgen Biotech Wonderful memories at KSSCR International Symposium 2019 On September 26-28, 2019, the 3-days KSSCR International Symposium 2019 was successfully ended in Grand Hilton Seoul, South Korea. 2019 ISSCR/KSSCR International Symposium is a joint meeting of the Korean Society for Stem Cell Research (KSSCR) and th... Posted by Site editor|2019-10-08 LearnMore
- Recombinant Human Serum Albumin(OsrHSA) From Rice Was Approved By USA FDA For Clinical Study On August 10, 2019, Wuhan Healthgen Biotechnology Co., Ltd. received approval from the FDA of the United States for clinical trials on OsrHSA injection that was produced from rice expression platform. This is the first blood product from China which was approved for clinical tr... Posted by Site editor|2019-08-10 LearnMore
- Healthgen Biotech will attend the World Advanced Therapies & Regenerative Medicine Congress 2019 in London, UK Date: 5/15/2019 - 5/17/2019 Venue: Business Design Centre Address: Business Design Centre Ltd,, 52 Upper St, London N1 0QH Booth No: #6 The World Advanced Therapies&Regenerative Medicine Congress is Europe’s most important advance... Posted by Site editor|2019-05-04 LearnMore
Copyright ® Wuhan Healthgen Biotechnology Corp. All rights reserved. Terms and Conditions of Use
鄂ICP备12013293号-3
